No black box warning on record for Glycopyrrolate Oral Solution

As of the latest FDA labeling reviewed, Glycopyrrolate Oral Solution (GLYCOPYRROLATE ORAL SOLUTION) does not carry a black box warning. Standard warnings and precautions still apply — see the full Glycopyrrolate Oral Solution medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Constipation or Intestinal Pseudo-obstruction Constipation is a common dose-limiting adverse reaction which sometimes leads to glycopyrrolate discontinuation [see Adverse Reactions (6.1)]. Assess patients for constipation, particularly within 4-5 days of initial dosing or after a dose increase. Intestinal pseudo-obstruction has been reported and may present as abdomi

No black box warning on record for Glycopyrrolate Oral Solution

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Constipation or Intestinal Pseudo-obstruction Constipation is a common dose-limiting adverse reaction which sometimes leads to glycopyrrolate discontinuation [see Adverse Reactions (6.1)]. Assess patients for constipation, particularly within 4-5 days of initial dosing or after a dose increase. Intestinal pseudo-obstruction has been reported and may present as abdomi

Glycopyrrolate Oral Solution Black Box Warning

No black box warning on record for Glycopyrrolate Oral Solution

Other warnings & precautions

Glycopyrrolate Oral Solution Black Box Warning

No black box warning on record for Glycopyrrolate Oral Solution

Other warnings & precautions